circulating tumor cells
Wednesday 31 May 2006
circulating tumoral cells, CTCs, circulating cancer cells
Malignant cells circulate in the bloodstream of patients with solid tumors.
Personalized cancer medicine requires the development of tumor-specific biomarkers to optimize selection of targeted therapies and to better assess response to therapy.
Current efforts in several tumor types have shown that patients in whom circulating tumor cells (CTCs) are detected have an inferior prognosis relative to those in whom CTCs are not detected and that the elimination or decrease of CTCs following treatment is associated with improved clinical outcomes.
Technological advances in the detection, isolation, capture, and characterization of CTCs from phlebotomy samples obtained in a routine clinical practice setting have enabled the evaluation of different CTC biomarkers.
Unmet needs in cancer diagnosis and treatment where CTC biomarkers have been studied include determining prognosis, assessing the effects of treatment, and as a source of tumor for the biologic identification and characterization of determinants to predict sensitivity to one form of treatment versus another and to understand mechanisms of treatment resistance.
At present, there is no single definition of a CTC and no single CTC "biomarker." Rather, multiple assays (tests) are in development for CTC biomarkers.
However, before the role of any biomarker in medical decision making can be determined, it is essential that the assays used to measure the biomarker are analytically validated in a sequence of trials to generate the evidence to support the biomarker’s use in the given context of use.
It is against this background that this review focuses on the process of developing CTC biomarker assays, with the objective of outlining the necessary steps to qualify specific CTC tests for medical decision making in clinical practice or drug development. The potential for point-of-care tests is clear.
Biomarkers in CTCSs
biomarkers in circulating tumor cell
- DNA biomarkers in circulating tumor cells
- RNA biomarkers in circulating tumor cells
- miRNA biomarkers in circulating tumor cells
- protein biomarkers in circulating tumor cells
Punnoose EA, et al. Molecular biomarker analyses using circulating tumor cells. PLoS One. 2010;5(9):e12517. PMID: 20838621
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. Ligthart ST, Coumans FA, Bidard FC, Simkens LH, Punt CJ, de Groot MR, Attard G, de Bono JS, Pierga JY, Terstappen LW. PLoS One. 2013 Jun 27;8(6):e67148 . PMID: 23826219 [Free]
Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Lianidou ES, Mavroudis D, Georgoulias V. Br J Cancer. 2013 Jun 25;108(12):2426-32. doi : 10.1038/bjc.2013.265 PMID: 23756869
Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias V, Lianidou E. BMC Cancer. 2011 Oct 4;11:422. PMID: 21967632 [Free]
Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R. BMC Cancer. 2010 Dec 3;10:666. PMID: 21129172 [Free]
Essentials of circulating tumor cells for clinical research and practice. Liberko M, Kolostova K, Bobek V. Crit Rev Oncol Hematol. 2013 Jul 4. doi : pii: S1040-8428(13)00096-6.10.1016/j.critrevonc.2013.05.002 PMID: 23830807
Prostate Cancer: A Change in Circulating Tumor Cells Detection Has High Potential in the Prediction. October 11, 2013. By European Association of Urology http://www.sciencenewsline.com/articles/2013101116100003.html
Circulating tumor cells and DNA as liquid biopsies. Heitzer E, Auer M, Ulz P, Geigl JB, Speicher MR. Genome Med. 2013 Aug 23;5(8):73. PMID: 23998943
Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Uenosono Y, Arigami T, Kozono T, Yanagita S, Hagihara T, Haraguchi N, Matsushita D, Hirata M, Arima H, Funasako Y, Kijima Y, Nakajo A, Okumura H, Ishigami S, Hokita S, Ueno S, Natsugoe S. Cancer. 2013 Aug 20. doi : 10.1002/cncr.28309 PMID: 23963829
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Danila DC, Pantel K, Fleisher M, Scher HI. Cancer J. 2011 Nov-Dec;17(6):438-50. doi : 10.1097/PPO.0b013e31823e69ac. Review PMID: 22157288
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Danila DC, Pantel K, Fleisher M, Scher HI. Cancer J. 2011 Nov-Dec;17(6):438-50. PMID: 22157288
Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients
Diego M Marzese et al. Expert Review of Molecular Diagnostics, November 2013, Vol. 13, No. 8, Pages 827-844, doi : 10.1586/14737159.2013 845088
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF V600E : A non-invasive tool panel for early detection of thyroid cancer. Zane M, Agostini M, Enzo MV, Casal Ide E, Del Bianco P, Torresan F, Merante Boschin I, Pennelli G, Saccani A, Rubello D, Nitti D, Pelizzo MR. Biomed Pharmacother. 2013 Jul 5. doi : pii:S0753-3322(13)00083-8 10.1016/j.biopha.2013.06.007. PMID: 23931930
Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Lianidou ES, Mavroudis D, Georgoulias V. Br J Cancer. 2013 Jun 25;108(12):2426-32. doi : 10.1038/bjc.2013.265 Epub 2013 Jun 11. Review. PMID: 23756869
Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients. Vallée A, Marcq M, Bizieux A, Kouri CE, Lacroix H, Bennouna J, Douillard JY, Denis MG. Lung Cancer. 2013 Aug 19. doi : pii:S0169-5002(13)00377-2.10.1016/j.lungcan.2013.08.014 PMID: 24007628